Desjardins Global Asset Management Inc. Biogen Inc. Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 446 shares of BIIB stock, worth $66,984. This represents 0.01% of its overall portfolio holdings.
Number of Shares
446
Previous 3,196
86.05%
Holding current value
$66,984
Previous $821,000
85.99%
% of portfolio
0.01%
Previous 0.09%
Shares
8 transactions
Others Institutions Holding BIIB
# of Institutions
1,037Shares Held
126MCall Options Held
1.13MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.5 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.45 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.18 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.1 Billion0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY5.26MShares$790 Million0.08% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.6B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...